12 Best Multibagger Stocks to Buy in 2025

Page 6 of 11

6. Summit Therapeutics Inc. (NASDAQ:SMMT)

Number of Hedge Fund Holders: 25

Stock Price Return in the last twelve months: 306%

Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company focused on developing innovative medicines for infectious diseases and oncology. Its pipeline includes targeted therapies designed to address antibiotic-resistant bacterial infections and novel cancer treatments. The company collaborates with research institutions and industry partners to advance its drug candidates through clinical development. SMMT operates primarily in the United States and international markets, working to bring new treatment options to patients with unmet medical needs.

Summit Therapeutics Inc. (NASDAQ:SMMT) has made significant progress with its lead investigational asset – Ivonescimab – reaching several meaningful milestones in Q4 2024 and early 2025. The company announced a clinical trial collaboration with Pfizer to evaluate Ivonescimab in combination with multiple Pfizer antibody drug conjugates in unique solid tumor settings, with trials expected to start by mid-2025. SMMT completed enrollment in HARMONi, their global Phase III trial for EGFR mutated advanced non-small cell lung cancer patients, and received Fast Track designation, with top line data expected in mid-2025.

Summit Therapeutics Inc. (NASDAQ:SMMT) expanded its HARMONi-3 trial to include both squamous and non-squamous histologies, significantly increasing the addressable patient population by 2-3x. More than 2,300 patients have been treated with Ivonescimab in clinical trials since 2019, and the drug was featured in 14 publications across 7 tumor types and selected for 5 oral presentations at major medical conferences in 2024. Currently, between SMMT and its partner Akeso, 4 Phase III trials have completed enrollment, 2 are awaiting top line data, and 5 Phase III trials are ongoing across various cancer types. The company ended 2024 with a strong cash position of approximately $412 million and is debt-free, positioning it well to continue executing its clinical trials. With a stock price return of 306% in the last year, SMMT is one of the best multibagger stocks to buy in 2025.

Page 6 of 11